Drug Development
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
REGENXBIO
PR-01-25-NI-12Jan 14, 2025
Transient Expression
Overcoming Limitations with Transient Protein Expression to Accelerate Development
Cenk Sumen, Ph.D.
MaxCyte
PAO-10-022-CL-02Oct 11, 2022